Stock Market News1 day J&J’s Depression Drug Spravato Gets FDA Nod for Monotherapy Use Zacks
The FDA approves Johnson & Johnson’s sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
XThe FDA approves Johnson & Johnson’s sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
X